LXRX to expect Phase III HCM data in Q1; resubmits type 1 diabetes NDA
LXRX is advancing sotagliflozin in HCM with Phase III data expected in Q1. The company is also preparing a type 1 diabetes NDA resubmission after meeting FDA safety requirements.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.